# Glioblastoma Treatment With Irradiation and Olaptesed Pegol (NOX-A12) in MGMT Unmethylated Patients

Source: https://onco.cc/trials/nct04121455/  
OnCo record `nct04121455` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Bevacizumab, Pembrolizumab and Temozolomide in glioma & glioblastoma, run by TME Pharma AG, active and no longer recruiting.

## Summary

Glioblastoma Treatment With Irradiation and Olaptesed Pegol (NOX-A12) in MGMT Unmethylated Patients is a phase 1/2 interventional study registered as NCT04121455 by TME Pharma AG, with 117 participants enrolled, started 2019-09-12 and due to reach its primary completion in 2028-12. Interventions recorded: Olaptesed pegol, Radiotherapy, Bevacizumab, Pembrolizumab and Temozolomide (TMZ).

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT04121455
- Phase: 1/2
- Setting: Single-arm, Dose-escalation Phase 1/2 Study of Olaptesed Pegol (NOX-A12) in Combination With Irradiation in Inoperable or Partially Resected First-line Glioblastoma Patients With Unmethylated MGMT Promoter With a Multiple-arm Expansion Group
- Sponsor: TME Pharma AG
- Enrolled: 117

## Sources

- ClinicalTrials.gov NCT04121455: https://clinicaltrials.gov/study/NCT04121455

## Connected records

- cancers: [Glioma & glioblastoma](https://onco.cc/cancers/glioblastoma/)
- drugs: [Bevacizumab](https://onco.cc/drugs/bevacizumab/), [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/), [Temozolomide](https://onco.cc/drugs/temozolomide/)

---
JSON: https://onco.cc/api/v1/entities/nct04121455.json